|
1
|
Alquier-Bouffard A, Franck F,
Joubert-Zakeyh J, Barthélémy I, Mansard S, Ughetto S,
Aublet-Cuvelier B, Déchelotte PJ, Mondié JM, Souteyrand P and
D'incan M: Regression in primary cutaneous melanoma is not
predictive for sentinel lymph node micrometastasis. Ann Dermatol
Venereol. 134:521–525. 2007.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McGovern VJ, Shaw HM and Milton GW:
Prognosis in patients with thin malignant melanoma: Influence of
regression. Histopathology. 7:673–680. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abramova L, Slingluff CL Jr and Patterson
JW: Problems in the interpretation of apparent ‘radial growth
phase’ malignant melanomas that metastasize. J Cutan Pathol.
29:407–414. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Balch CM, Gershenwald JE, Soong SJ,
Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG,
Ding S, et al: Final version of 2009 AJCC melanoma staging and
classification. J Clin Oncol. 27:6199–6206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zurac S, Negroiu G, Petrescu S, Andrei R,
Tebeica T, Popp C, Musţată R, Neagu M, Constantin C, Solovan C, et
al: Spectrum of morphologic alterations of regression in cutaneous
melanoma - potential for improving disease prognosis. Rom J Intern
Med. 50:145–153. 2012.PubMed/NCBI
|
|
6
|
Andrei R, Zurac S, Socoliuc C and
Staniceanu F: Variation in expression of metalloproteinases in
cutaneous melanoma with regression, possible indicator of tumor
heterogeneity. DermatoVenerol (Buc). 60:133–145. 2015.
|
|
7
|
Trau H, Kopf AW, Rigel DS, Levine J,
Rogers G, Levenstein M, Bart RS, Mintzis MM and Friedman RJ:
Regression in malignant melanoma. J Am Acad Dermatol. 8:363–368.
1983. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kaur C, Thomas RJ, Desai N, Green MA,
Lovell D, Powell BW and Cook MG: The correlation of regression in
primary melanoma with sentinel lymph node status. J Clin Pathol.
61:297–300. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shaw HM, Rivers JK, McCarthy SW and
McCarthy WH: Cutaneous melanomas exhibiting unusual biologic
behavior. World J Surg. 16:196–202. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guitart J, Lowe L, Piepkorn M, Prieto VG,
Rabkin MS, Ronan SG, Shea CR, Tron VA, White W and Barnhill RL:
Histological characteristics of metastasizing thin melanomas: A
case-control study of 43 cases. Arch Dermatol. 138:603–608. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Blessing K and McLaren KM: Histological
regression in primary cutaneous melanoma: Recognition, prevalence
and significance. Histopathology. 20:315–322. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Paladugu RR and Yonemoto RH: Biologic
behavior of thin malignant melanomas with regressive changes. Arch
Surg. 118:41–44. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oláh J, Gyulai R, Korom I, Varga E and
Dobozy A: Tumour regression predicts higher risk of sentinel node
involvement in thin cutaneous melanomas. Br J Dermatol.
149:662–663. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Socrier Y, Lauwers-Cances V, Lamant L,
Garrido I, Lauwers F, Lopez R, Rochaix P, Chevreau C, Payoux P,
Viraben R, et al: Histological regression in primary melanoma: Not
a predictor of sentinel lymph node metastasis in a cohort of 397
patients. Br J Dermatol. 162:830–834. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fontaine D, Parkhill W, Greer W and Walsh
N: Partial regression of primary cutaneous melanoma: Is there an
association with sub-clinical sentinel lymph node metastasis? Am J
Dermatopathol. 25:371–376. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liszkay G, Orosz Z, Péley G, Csuka O,
Plótár V, Sinkovics I, Bánfalvi T, Fejõs Z, Gilde K and Kásler M:
Relationship between sentinel lymph node status and regression of
primary malignant melanoma. Melanoma Res. 15:509–513. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Emanuel PO, Mannion M and Phelps RG:
Complete regression of primary malignant melanoma. Am J
Dermatopathol. 30:178–181. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
High WA, Stewart D, Wilbers CRH, Cockerell
CJ, Hoang MP and Fitzpatrick JE: Completely regressed primary
cutaneous malignant melanoma with nodal and/or visceral metastases:
A report of 5 cases and assessment of the literature and diagnostic
criteria. J Am Acad Dermatol. 53:89–100. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Klebanoff CA, Acquavella N, Yu Z and
Restifo NP: Therapeutic cancer vaccines: Are we there yet? Immunol
Rev. 239:27–44. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Faries MB and Morton DL: Therapeutic
vaccines for melanoma: Current status. BioDrugs. 19:247–260. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
van Kempen LC, van Muijen GN and Ruiter
DJ: Stromal responses in human primary melanoma of the skin. Front
Biosci. 10:2922–2931. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nikitovic D, Mytilinaiou M, Berdiaki A,
Karamanos NK and Tzanakakis GN: Heparan sulfate proteoglycans and
heparin regulate melanoma cell functions. Biochim Biophys Acta.
1840:2471–2481. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chalkiadaki G, Nikitovic D, Berdiaki A,
Katonis P, Karamanos NK and Tzanakakis GN: Heparin plays a key
regulatory role via a p53/FAK-dependent signaling in melanoma cell
adhesion and migration. IUBMB Life. 63:109–119. 2011.PubMed/NCBI
|
|
24
|
Chalkiadaki G, Nikitovic D, Katonis P,
Berdiaki A, Tsatsakis A, Kotsikogianni I, Karamanos NK and
Tzanakakis GN: Low molecular weight heparin inhibits melanoma cell
adhesion and migration through a PKCa/JNK signaling pathway
inducing actin cytoskeleton changes. Cancer Lett. 312:235–244.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nikitovic D, Assouti M, Sifaki M, Katonis
P, Krasagakis K, Karamanos NK and Tzanakakis GN: Chondroitin
sulfate and heparan sulfate-containing proteoglycans are both
partners and targets of basic fibroblast growth factor-mediated
proliferation in human metastatic melanoma cell lines. Int J
Biochem Cell Biol. 40:72–83. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sifaki M, Assouti M, Nikitovic D,
Krasagakis K, Karamanos NK and Tzanakakis GN: Lumican, a small
leucine-rich proteoglycan substituted with keratan sulfate chains
is expressed and secreted by human melanoma cells and not normal
melanocytes. IUBMB Life. 58:606–610. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Moro N, Mauch C and Zigrino P:
Metalloproteinases in melanoma. Eur J Cell Biol. 93:23–29. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Slootweg PJ and Zurac S: Prognostic and
predictive value of epithelial to mesenchymal transition-associated
markers in oral squamous cell carcinoma. Curr Proteomics.
10:218–227. 2013. View Article : Google Scholar
|
|
31
|
Duan JX, Rapti M, Tsigkou A and Lee MH:
Expanding the activity of tissue inhibitors of metalloproteinase
(TIMP)-1 against surface-anchored metalloproteinases by the
replacement of its C-terminal domain: Implications for anti-cancer
effects. PLoS One. 10:e01363842015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bourboulia D and Stetler-Stevenson WG:
Matrix metalloproteinases (MMPs) and tissue inhibitors of
metalloproteinases (TIMPs): Positive and negative regulators in
tumor cell adhesion. Semin Cancer Biol. 20:161–168. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Baker AH, Edwards DR and Murphy G:
Metalloproteinase inhibitors: Biological actions and therapeutic
opportunities. J Cell Sci. 115:3719–3727. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Visse R and Nagase H: Matrix
metalloproteinases and tissue inhibitors of metalloproteinases:
Structure, function, and biochemistry. Circ Res. 92:827–839. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kovatsi L, Batzios S, Nikolaou K, Fragou
D, Njau S, Tsatsakis A, Karakiulakis G and Papakonstantinou E:
Alterations in serum MMP and TIMP concentrations following chronic
heroin abuse. Toxicol Mech Methods. 23:377–381. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsarouhas K, Soufla G, Apostolakis S,
Zaravinos A, Panagiotou M, Khoury M, Hassoulas JA, Tsatsakis AM and
Spandidos DA: Transcriptional regulation of TIMPs in ascending
aorta aneurysms. Thromb Res. 126:399–405. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Das AM, Koljenović S, Oude Ophuis CM, van
der Klok T, Galjart B, Nigg AL, van Cappellen WA, Noordhoek Hegt V,
Dinjens WN, Atmodimedjo PN, et al: Association of TIMP3 expression
with vessel density, macrophage infiltration and prognosis in human
malignant melanoma. Eur J Cancer. 53:135–143. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gonzalez-Gomez P, Bello MJ, Alonso ME,
Amiñoso C, Lopez-Marin I, De Campos JM, Isla A, Gutierrez M and Rey
JA: Promoter methylation status of multiple genes in brain
metastases of solid tumors. Int J Mol Med. 13:93–98.
2004.PubMed/NCBI
|
|
39
|
Xia Y and Wu S: Tissue inhibitor of
metalloproteinase 2 inhibits activation of the β-catenin signaling
in melanoma cells. Cell Cycle. 14:1666–1674. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wen X, Wu JQ, Peng W, Feng JF and Tang JH:
MicroRNA-377 predicts poor clinical outcome of gastric cancer and
induces tumorigenesis by targeting multiple tumor-suppressor genes.
Oncol Rep. 34:203–210. 2015.PubMed/NCBI
|
|
41
|
Toricelli M, Melo FH, Peres GB, Silva DC
and Jasiulionis MG: Timp1 interacts with beta-1 integrin and CD63
along melanoma genesis and confers anoikis resistance by activating
PI3-K signaling pathway independently of Akt phosphorylation. Mol
Cancer. 12:222013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chunhacha P, Sriuranpong V and
Chanvorachote P: Epithelial-mesenchymal transition mediates anoikis
resistance and enhances invasion in pleural effusion-derived human
lung cancer cells. Oncol Lett. 5:1043–1047. 2013.PubMed/NCBI
|
|
43
|
Kluger HM, Hoyt K, Bacchiocchi A, Mayer T,
Kirsch J, Kluger Y, Sznol M, Ariyan S, Molinaro A and Halaban R:
Plasma markers for identifying patients with metastatic melanoma.
Clin Cancer Res. 17:2417–2425. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tarhini AA, Lin Y, Yeku O, LaFramboise WA,
Ashraf M, Sander C, Lee S and Kirkwood JM: A four-marker signature
of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival
in high-risk surgically resected melanoma. J Transl Med. 12:192014.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ricca TI, Liang G, Suenaga AP, Han SW,
Jones PA and Jasiulionis MG: Tissue inhibitor of metalloproteinase
1 expression associated with gene demethylation confers anoikis
resistance in early phases of melanocyte malignant transformation.
Transl Oncol. 2:329–340. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zurac S, Negroiu G, Andrei R, Petrescu S,
Tebeica T, Petre M, Neagu M, Constantin C, Chitu V, Salavastru C,
et al: Inflammatory infiltrate in melanoma with regression as
prognostic parameter. Virchows Arch. 463:1272013.
|
|
47
|
Neagu M, Constantin C and Zurac S: Immune
parameters in the prognosis and therapy monitoring of cutaneous
melanoma patients: Experience, role, and limitations. BioMed Res
Int. 2013:1079402013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Neagu M: The immune system - a hidden
treasure for biomarker discovery in cutaneous melanoma. Adv Clin
Chem. 58:89–140. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bulman A, Neagu M and Constantin C:
Immunomics in skin cancer - improvement in diagnosis, prognosis and
therapy monitoring. Curr Proteomics. 10:202–217. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Spandidos DA: A unified theory for the
development of cancer. Biosci Rep. 6:691–708. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Spandidos DA: The cancer story. Cancer
Biol Ther. 3:1184–1186. 2004. View Article : Google Scholar : PubMed/NCBI
|
